WebMD

Navigating Bullous Pemphigoid: What to Know About Dupixent

Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...
Seeking Alpha

Dupixent® (dupilumab injection) approved in Canada for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD)

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Monthly Prescribing Reference

FDA Approval Allows for Use of Dupixent Prefilled Pens in Younger Patients

Dupixent single-dose prefilled pens feature a hidden needle and single-press auto-injection. The Food and Drug Administration (FDA) has expanded the approval of the Dupixent ® (dupilumab) single-dose ...
Nasdaq

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and ...
Seeking Alpha

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD ...
Finanznachrichten

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...